Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial (PDHA1), is an essential mitochondrial enzyme subunit responsible for catalyzing the oxidative decarboxylation of pyruvate to acetyl-CoA, the crucial step linking glycolysis to the TCA cycle and cellular energy production. The enzyme is a heterotetramer consisting of two alpha and two beta subunits. PDHA1 mutations cause pyruvate dehydrogenase complex deficiency, leading to metabolic and neurological disorders due to impaired ATP generation. The activity of the PDH complex is regulated by phosphorylation, cofactors (notably thiamine pyrophosphate), and pharmacological modifiers. It is a well-studied target for the treatment of inherited and acquired metabolic diseases.
Allosteric activation or stabilization of the enzyme complex; Cofactor supplementation (thiamine to enhance enzyme activity); Pharmacological activation (dichloroacetate inhibits pyruvate dehydrogenase kinase, activating the complex)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial (PDHA1).